Colinz Labs — 360° view

Colinz Labs, a company in the Pharmaceuticals industry, reported revenue of ₹1.55 crore and net profit of ₹0.13 crore for the September 2026 quarter.

Colinz Labs (BSE: COLINZ) closed at ₹64.25 on 20 Nov 2026, up 49.2% over the past year. Its market capitalisation is ₹16 crore and it trades at 33.0 times earnings.

Share price
₹64.25 (20 Nov 2026)
Market cap
₹16 Cr (20 Nov 2026)
P/E
33.04 (20 Nov 2026)
Revenue
₹2 Cr (September 2026 quarter)
Net profit
₹0 Cr (September 2026 quarter)
ROCE
7.20% (FY26)
ROE
5.23% (FY26)
Book value
₹50.4 (FY26)
Dividend yield
0.00% (FY26)
52-week high / low
₹87.91 / ₹36.58 (20 Nov 2026)
1-year return
49.2% (to 20 Nov 2026)
Sector
Healthcare
Industry
Pharmaceuticals
Symbol
BSE: COLINZ

Incorporated in 1986, Colinz Laboratories is in the business of manufacturing and trading in pharmaceutical formulations

Descriptive research only, not investment advice. Evenstocks is not a SEBI-registered investment adviser.